Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens

References

• D’herelle F. On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D’Herelle, presented by Mr. Roux. 1917. Res. Microbiol.158(7), 553–554 (2007).
   PubMed Web of Science ®Google Scholar
• D’herelle F. An address on bacteriophagy and recovery from infectious diseases. Can. Med. Assoc. J.24(5), 619–628 (1931).
   PubMedGoogle Scholar
• D’herelle F. Bacterial mutations. Yale. J. Biol. Med.4(1), 55–61 (1931).
   PubMedGoogle Scholar
• Twort FW. Further investigations on the nature of ultra-microscopic viruses and their cultivation. J. Hyg. (Lond.)36(2), 204–235 (1936).
   PubMedGoogle Scholar
• Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob. Agents Chemother.45(3), 649–659 (2001).
   PubMed Web of Science ®Google Scholar
• Kutter E, De Vos D, Gvasalia G et al. Phage therapy in clinical practice: treatment of human infections. Curr. Pharmaceu. Biotechnol.11(1), 69–86 (2010).
   PubMed Web of Science ®Google Scholar
• French G. The continuing crisis in antibiotic resistance. Int. J. Antimicrob. Agents36, S3–S7 (2010).
   PubMed Web of Science ®Google Scholar
• Gould I. Antibiotic resistance: the perfect storm. Int. J. Antimicrob. Agents34, S2–S5 (2009).
   PubMed Web of Science ®Google Scholar
• Martinez JL, Fajardo A, Garmendia L et al. A global view of antibiotic resistance. FEMS Microbiol. Rev.33(1), 44–65 (2009).
   PubMed Web of Science ®Google Scholar
• Gootz TD. The global problem of antibiotic resistance. Crit. Rev. Immunol.30(1), 79–93 (2010).
   PubMed Web of Science ®Google Scholar
• Ippolito G, Leone S, Lauria FN, Nicastri E, Wenzel RP. Methicillin-resistant Staphylococcus aureus: the superbug. Int. J. Infect. Dis.14(Suppl. 4), S7–S11 (2010).
   PubMed Web of Science ®Google Scholar
• Wang JL, Hsueh PR. Therapeutic options for infections due to vancomycin-resistant Expert Opin. Pharmacother.10(5), 785–796 (2009).
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Carvalhaes CG, Picão RC, Gales AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev. Anti Infect. Ther.8(1), 71–93 (2010).
   PubMed Web of Science ®Google Scholar
• Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int. J. Antimicrob. Agents37(5), 415–419 (2011).
   PubMed Web of Science ®Google Scholar
• Lee AS, Huttner B, Harbarth S. Control of methicillin-resistant Staphylococcus aureus. Infect. Dis. Clin. N. Am.25(1), 155–179 (2011).
   PubMed Web of Science ®Google Scholar
• Hsu J, Abad C, Dinh M, Safdar N. Prevention of endemic healthcare-associated Clostridium difficile infection: reviewing the evidence. Am. J. Gastroenterol.105(11), 2327–2339 (2010).
   PubMed Web of Science ®Google Scholar
• Goff DA. Antimicrobial stewardship: bridging the gap between quality care and cost. Curr. Opin. Infect. Dis.24, S11 (2011).
   PubMed Web of Science ®Google Scholar
• Glupczynski Y, Bogaerts P, Deplano A et al. Detection and characterization of class A extended-spectrum–lactamase-producing Pseudomonas aeruginosa isolates in Belgian hospitals. J. Antimicrob. Chemother.65(5), 866 (2010).
   PubMed Web of Science ®Google Scholar
• Saleem AF, Ahmed I, Mir F, Ali SR, Zaidi AKM. Pan-resistant acinetobacter infection in neonates in Karachi, Pakistan. J. Infect. Develop. Countries4(1), 30–37 (2009).
   PubMed Web of Science ®Google Scholar
• Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st Century – a clinical super-challenge. N. Engl. J. Med.360(5), 439–443 (2009).
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis.48(1), 1 (2009).
   PubMed Web of Science ®Google Scholar
• Abedon ST. Communication among phages, bacteria, and soil environments. In: Biocommunication of Soil Microorganisms. Witzany G (Ed.). Springer-Verlag, Heidelberg, Germany, 37–65 (2011).
   Google Scholar
• Ptashne M. A Genetic Switch : Phage λ Revisited. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA (2004).
   Google Scholar
• Boyd EF, Brussow H. Common themes among bacteriophage-encoded virulence factors and diversity among the bacteriophages involved. Trends Microbiol.10(11), 521–529 (2002).
   PubMed Web of Science ®Google Scholar
• Tinsley CR, Bille E, Nassif X. Bacteriophages and pathogenicity: more than just providing a toxin? Microbes Infect.8(5), 1365–1371 (2006).
   PubMed Web of Science ®Google Scholar
• Hyman P, Abedon ST. Bacteriophage host range and bacterial resistance. Adv. Appl. Microbiol.70, 217–248 (2010).
   PubMed Web of Science ®Google Scholar
• Chen J, Novick RP. Phage-mediated intergeneric transfer of toxin genes. Science323(5910), 139 (2009).
   PubMed Web of Science ®Google Scholar
• Labrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms. Nat. Rev. Microbiol.8(5), 317–327 (2010).
   PubMed Web of Science ®Google Scholar
• Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr. Pharmaceu. Biotechnol.11(1), 28–47 (2010).
   PubMed Web of Science ®Google Scholar
• Goodridge LD. Designing phage therapeutics. Curr. Pharmaceu. Biotechnol.11(1), 15–27 (2010).
   PubMed Web of Science ®Google Scholar
• Stephenson J. The art of ‘HAART’: researchers probe the potential and limits of aggressive HIV treatments. JAMA277(8), 614 (1997).
   PubMed Web of Science ®Google Scholar
• Poole K. Mechanisms of bacterial biocide and antibiotic resistance. J. Appl. Microbiol.92, S55–S64 (2002).
   PubMed Web of Science ®Google Scholar
• Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J. Antimicrobial Chemotherapy59(4), 772 (2007).
   PubMed Web of Science ®Google Scholar
• Auckland C, Teare L, Cooke F et al. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J. Antimicrobial Chemother.50(5), 743 (2002).
   PubMed Web of Science ®Google Scholar
• Merril CR, Scholl D, Adhya SL. The prospect for bacteriophage therapy in Western medicine. Nat. Rev. Drug Discov.2(6), 489–497 (2003).
   PubMed Web of Science ®Google Scholar
• Summers WC. Bacteriophage therapy. Ann. Rev. Microbiol.55(1), 437–451 (2001).
   PubMed Web of Science ®Google Scholar
• Sulakvelidze A. Phage therapy: an attractive option for dealing with antibiotic-resistant bacterial infections. Drug Discovery Today10(12), 807–809 (2005).
   PubMed Web of Science ®Google Scholar
• Mattey M, Spencer J. Bacteriophage therapy – cooked goose or Phoenix rising? Curr. Opin. Biotechnol.19(6), 608–612 (2008).
   PubMed Web of Science ®Google Scholar
• Kutter E, Sulakvelidze A. Bacteriophages: Biology and Applications. CRC Press, London, UK; NY, FL and Washington DC, USA (2005).
   Google Scholar
• Skurnik M. Viruses vs superbugs: a solution to the antibiotic crisis? JAMA297(6), 644 (2007).
   Google Scholar
• Abedon ST, Kuhl SJ, Blasdel RG, Kutter EM. Phage treatment of human infections. Bacteriophage1(2), 66–68 (2011).
   PubMedGoogle Scholar
• Mahony J, O Mca, Ross RP, Van Sinderen D. Bacteriophages as biocontrol agents of food pathogens. Curr. Opin. Biotechnol.22(2), 157–163 (2011).
   PubMed Web of Science ®Google Scholar
• Harper D, Enright M. Bacteriophages for the treatment of Pseudomonas aeruginosa infections. J. Appl. Microbiol.111(1), 1–7 (2011).
   PubMed Web of Science ®Google Scholar
• Pirnay JP, De Vos D, Verbeken G et al. The phage therapy paradigm: pret-a-porter or sur-mesure? Pharmaceu. Res.28(4), 934–937 (2011).
   Google Scholar
• Cima G. Searching for self-replicating antimicrobials. J. Am. Vet. Med. Assoc.237(12), 1336–1339 (2010).
   PubMed Web of Science ®Google Scholar
• Monk AB, Rees CD, Barrow P, Hagens S, Harper DR. Bacteriophage applications: where are we now? Lett. Appl. Microbiol.51(4), 363–369 (2010).
   PubMed Web of Science ®Google Scholar
• Chanishvili N, Sharp R. A literature review of the practical application of bacteriophage research. Eliava Institute of Bacteriophage, Microbiology and Virology, Tbilisi, Georgia (2009).
   Google Scholar
• Kutateladze M, Adamia R. Phage therapy experience at the Eliava Institute. Med. Mal. Infect.38(8), 426–430 (2008).
   PubMed Web of Science ®Google Scholar
• Weber D, Browska B, Mulczyk M, Górski A. Bacteriophage therapy of bacterial infections: an update of our institute’s experience. Arch. Immunol. Ther. Exp.48, 547–551 (2000).
   PubMedGoogle Scholar
• Slopek S, Durlakowa I, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections. III. Detailed evaluation of the results obtained in further 150 cases. Arch. Immunol. Ther. Exp. (Warsz)32(3), 317–335 (1984).
   PubMed Web of Science ®Google Scholar
• Slopek S, Durlakowa I, Weber-Dabrowska B, Kucharewicz-Krukowska A, Dabrowski M, Bisikiewicz R. Results of bacteriophage treatment of suppurative bacterial infections. II. Detailed evaluation of the results. Arch. Immunol. Ther. Exp. (Warsz)31(3), 293–327 (1983).
   PubMed Web of Science ®Google Scholar
• Slopek S, Durlakowa I, Weber-Dabrowska B, Kucharewicz-Krukowska A, Dabrowski M, Bisikiewicz R. Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results. Arch. Immunol. Ther. Exp. (Warsz)31(3), 267–291 (1983).
   PubMed Web of Science ®Google Scholar
• Slopek S, Kucharewicz-Krukowska A, Weber-Dabrowska B, Dabrowski M. Results of bacteriophage treatment of suppurative bacterial infections. VI. Analysis of treatment of suppurative staphylococcal infections. Arch. Immunol. Ther. Exp. (Warsz)33(2), 261–273 (1985).
   PubMed Web of Science ®Google Scholar
• Slopek S, Kucharewicz-Krukowska A, Weber-Dabrowska B, Dabrowski M. Results of bacteriophage treatment of suppurative bacterial infections. V. Evaluation of the results obtained in children. Arch. Immunol. Ther. Exp. (Warsz)33(2), 241–259 (1985).
   PubMed Web of Science ®Google Scholar
• Slopek S, Kucharewicz-Krukowska A, Weber-Dabrowska B, Dabrowski M. Results of bacteriophage treatment of suppurative bacterial infections. IV. Evaluation of the results obtained in 370 cases. Arch. Immunol. Ther. Exp. (Warsz)33(2), 219–240 (1985).
   PubMed Web of Science ®Google Scholar
• Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986. Arch. Immunol. Ther. Exp.35, 569–583 (1987).
   PubMed Web of Science ®Google Scholar
• Letkiewicz S, Mi Dzybrodzki R, Klak M, Jonczyk E, Weber-Dabrowska B, Górski A. The perspectives of the application of phage therapy in chronic bacterial prostatitis. FEMS Immunol. Med. Microbiol.60(2), 99–112 (2010).
   PubMedGoogle Scholar
• Gorski A, Dabrowska K, Switala-Jele K et al. New insights into the possible role of bacteriophages in host defense and disease. Med. Immunol.2(1), 2 (2003).
   PubMedGoogle Scholar
• Gorski A, Kniotek M, Perkowska-Ptasin’ska A et al. Bacteriophages and transplantation tolerance. Transplant. Proc.38, 331–333 (2006).
   PubMed Web of Science ®Google Scholar
• Gorski A, Nowaczyk M, Weber-Dabrowska B et al. New insights into the possible role of bacteriophages in transplantation. 35, 2372–2373 (2003).
   Google Scholar
• Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, Gorski A. Bacterial viruses against viruses pathogenic for man? Virus Res.110(1–2), 1–8 (2005).
   PubMed Web of Science ®Google Scholar
• Miedzybrodzki R, Switala-Jelen K, Fortuna W et al. Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes. Virus Res.131(2), 233–242 (2008).
   PubMed Web of Science ®Google Scholar
• Pajtasz-Piasecka E, Rossowska J, Dus D, Weber-Dabrowska B, Zablocka A, Górski A. Bacteriophages support anti-tumor response initiated by DC-based vaccine against murine transplantable colon carcinoma. Immunol. Lett.116(1), 24–32 (2008).
   PubMed Web of Science ®Google Scholar
• Weber-Dabrowska B, Mulczyk M, Górski A. Bacteriophage therapy for infections in cancer patients. Clin. Appl. Immunol. Rev.1(3–4), 131–134 (2001).
   Google Scholar
• Laz RV, Chifiriuc M. Architecture and physiology of microbial biofilms. Roumanian Archiv. Microbiol. Immunol.69(2), 95 (2010).
   PubMedGoogle Scholar
• Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol.2(2), 95–108 (2004).
   PubMed Web of Science ®Google Scholar
• Dickschat JS. Quorum sensing and bacterial biofilms. Nat. Prod. Rep.27(3), 343 (2010).
   PubMed Web of Science ®Google Scholar
• Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob. Agents35(4), 322–332 (2010).
   PubMed Web of Science ®Google Scholar
• Sutherland IW, Hughes KA, Skillman LC, Tait K. The interaction of phage and biofilms. FEMS Microbiol. Lett.232(1), 1–6 (2004).
   PubMed Web of Science ®Google Scholar
• Hughes K, Sutherland I, Clark J, Jones M. Bacteriophage and associated polysaccharide depolymerases – novel tools for study of bacterial biofilms. J. Appl. Microbiol.85(3), 583–590 (1998).
   PubMed Web of Science ®Google Scholar
• Rice SA, Tan CH, Mikkelsen PJ et al. The biofilm life cycle and virulence of Pseudomonas aeruginosa are dependent on a filamentous prophage. ISME J.3(3), 271–282 (2008).
   PubMed Web of Science ®Google Scholar
• Webb JS, Lau M, Kjelleberg S. Bacteriophage and phenotypic variation in Pseudomonas aeruginosa biofilm development. J. Bacteriol.186(23), 8066 (2004).
   PubMed Web of Science ®Google Scholar
• Webb JS, Thompson LS, James S et al. Cell death in Pseudomonas aeruginosa biofilm development. J. Bacteriol.185(15), 4585 (2003).
   PubMed Web of Science ®Google Scholar
• Brady JM, Gray WA, Caldwell MA. The electron microscopy of bacteriophage-like particles in dental plaque. J. Dental Res.56(8), 991 (1977).
   PubMed Web of Science ®Google Scholar
• Serwer P, Hayes SJ, Lieman K, Griess GA. In situ fluorescence microscopy of bacteriophage aggregates. J. Microsc.228(Pt 3), 309–321 (2007).
   PubMed Web of Science ®Google Scholar
• Thomas JA, Rolando MR, Carroll CA et al. Characterization of Pseudomonas chlororaphis myovirus 201varphi2-1 via genomic sequencing, mass spectrometry, and electron microscopy. Virology376(2), 330–338 (2008).
   PubMed Web of Science ®Google Scholar
• Donlan RM. Biofilms and device-associated infections. Emerg. Infect. Dis.7(2), 277 (2001).
   PubMed Web of Science ®Google Scholar
• Curtin JJ, Donlan RM. Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob. Agents Chemother.50(4), 1268 (2006).
   PubMed Web of Science ®Google Scholar
• Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob. Agents Chemother.54(1), 397 (2010).
   PubMed Web of Science ®Google Scholar
• Lu TK, Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl Acad. Sci. USA104(27), 11197 (2007).
   PubMed Web of Science ®Google Scholar
• Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev.74(3), 417 (2010).
   PubMed Web of Science ®Google Scholar
• Heinemann JA, Ankenbauer RG, Amabile-Cuevas CF. Do antibiotics maintain antibiotic resistance? Drug Discovery Today5(5), 195–204 (2000).
   PubMed Web of Science ®Google Scholar
• Comeau AM, Tétart F, Trojet SN, Prère MF, Krisch H. Phage-antibiotic synergy (PAS): -lactam and quinolone antibiotics stimulate virulent phage growth. PLoS ONE2(8), e799 (2007).
   PubMed Web of Science ®Google Scholar
• Neu HC. The crisis in antibiotic resistance. Science257(5073), 1064 (1992).
   PubMed Web of Science ®Google Scholar
• Smith HW, Huggins MB, Shaw KM. The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. Microbiology133(5), 1111 (1987).
   Web of Science ®Google Scholar
• Smith HW, Huggins M. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. Microbiology128(2), 307 (1982).
   Web of Science ®Google Scholar
• Smith HW, Huggins M. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. Microbiology129(8), 2659 (1983).
   Web of Science ®Google Scholar
• Hübner CA, Jentsch TJ. Ion channel diseases. Hum. Mol. Gene.11(20), 2435 (2002).
   PubMed Web of Science ®Google Scholar
• Govan J, Harris G. Pseudomonas aeruginosa and cystic fibrosis: unusual bacterial adaptation and pathogenesis. Microbiol. Sci.3(10), 302 (1986).
   PubMedGoogle Scholar
• Hogardt M, Heesemann J. Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. Int. J. Med. Microbiol.300(8), 557–562 (2010).
   PubMed Web of Science ®Google Scholar
• Høiby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Fut. Microbiol.5(11), 1663–1674 (2010).
   PubMed Web of Science ®Google Scholar
• Debarbieux L, Leduc D, Maura D et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J. Infect. Dis.201(7), 1096 (2010).
   PubMed Web of Science ®Google Scholar
• Morello E, Saussereau E, Maura D et al. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS ONE6(2), e16963 (2011).
   PubMed Web of Science ®Google Scholar
• Harrison F. Microbial ecology of the cystic fibrosis lung. Microbiology153(4), 917 (2007).
   PubMed Web of Science ®Google Scholar
• Carmody LA, Gill JJ, Summer EJ et al. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J. Infect. Dis.201(2), 264 (2010).
   PubMed Web of Science ®Google Scholar
• Golshahi L, Seed KD, Dennis JJ, Finlay WH. Toward modern inhalational bacteriophage therapy: nebulization of bacteriophages of Burkholderia cepacia complex. J. Aerosol Med. Pulmonary Drug Deliv.21(4), 351–360 (2008).
   PubMed Web of Science ®Google Scholar
• Golshahi L, Lynch K, Dennis J, Finlay W. In vitro lung delivery of bacteriophages KS4 M and KZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J. Appl. Microbiol.110(1), 106–117 (2011).
   PubMed Web of Science ®Google Scholar
• Lacey R. Genetic basis, epidemiology, and future significance of antibiotic resistance in Staphylococcus aureus: a review. J. Clin. Pathol.26(12), 899 (1973).
   PubMed Web of Science ®Google Scholar
• Finland M. Emergence of antibiotic resistance in hospitals, 1935–1975. Rev. Infect. Dis.1(1), 4 (1979).
   PubMedGoogle Scholar
• Zimecki M, Artym J, Koci Ba M et al. Prophylactic effect of bacteriophages on mice subjected to chemotherapy-induced immunosuppression and bone marrow transplant upon infection with Staphylococcus aureus. Med. Microbiol. Immunol.199(2), 71–79 (2010).
   PubMed Web of Science ®Google Scholar
• Sunagar R, Patil SA, Kelmani CR. Bacteriophage therapy for Staphylococcus aureus bacteremia in streptozotocin-induced diabetic mice. Res. Microbiol.161(10), 854–860 (2010).
   PubMed Web of Science ®Google Scholar
• Sujata S. Step by step management of burns. McGraw-Hill Medical, New York City, NY, USA (2010).
   Google Scholar
• McVay CS, Velasquez M, Fralick JA. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob. Agents Chemother.51(6), 1934 (2007).
   PubMed Web of Science ®Google Scholar
• Kumari S, Harjai K, Chhibber S. Evidence to support the therapeutic potential of bacteriophage Kpn5 in burn wound infection caused by Klebsiella pneumoniae in BALB/c mice. J. Microbiol. Biotechnol.20(5), 935 (2010).
   PubMed Web of Science ®Google Scholar
• Bruttin A, Brussow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents Chemother.49(7), 2874 (2005).
   PubMed Web of Science ®Google Scholar
• Rhoads D, Wolcott R, Kuskowski M, Wolcott B, Ward L, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a Phase I safety trial. J. Wound Care18(6), 237 (2009).
   PubMedGoogle Scholar
• Wright A, Hawkins C, Änggård E, Harper D. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol.34(4), 349–357 (2009).
   PubMed Web of Science ®Google Scholar
• Linge J, Nilges M. Structural bioinformatics and NMR structure determination. Prac. Bioinformatics15, 123–137 (2008).
   Google Scholar
• Pouillot F, Blois H, Iris F. Genetically engineered virulent phage banks in the detection and control of emergent pathogenic bacteria. Biosecur. Bioterror.8(2), 155–169 (2010).
   PubMedGoogle Scholar
• Merril CR, Biswas B, Carlton R et al. Long-circulating bacteriophage as antibacterial agents. Proc. Natl Acad. Sci. USA93(8), 3188–3192 (1996).
   PubMed Web of Science ®Google Scholar